Abstract:BACKGROUND Epigallocatechin gallate (EGCG) is a polyhydroxy phenolic compound extracted from tea and its antitumor effect has received widespread attention. We explored the inhibitory effect of EGCG on dimethylhydrazine (DMH)-induced colorectal cancer (CRC) using a rat model, predicted the interaction between EGCG and CRC target genes using a database, and explained the EGCG associated target pathways and mechanisms in CRC.AIM To understand the inhibitory mechanisms of EGCG on CRC cell proliferation and identify its pharmacological targets by network pharmacology analysis.METHODS DMH (40 mg/kg, s.c., twice weekly for eight weeks) was used to induce CRC in rats. After model establishment, the rats were administered with EGCG (50, 100, or 200 mg/kg, p.o., once daily for eight weeks) and killed 12 and 20 wk after the start of the experiment. Formation of aberrant crypt foci and tumor was studied by histological analysis. Using network pharmacology analysis, candidate and collective targets of EGCG and CRC were identified, and Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes analyses were used to predict the pathways altered by EGCG.RESULTS At week 12, high-dose EGCG treatment significantly reduced the tumor formation rate, total number of tumors, cancerous and non-cancerous tumors, tumor volume, ascites formation, and aberrant crypt foci count. At week 20, all three doses of EGCG were effective. Seventy-eight collective targets of EGCG and CRC were identified, of which 28 genes were dysregulated in CRC. Kyoto Encyclopedia of Genes and Genomes and GO analyses showed that the dysregulated genes were enriched in hsa05210 (CRC), hsa04115 (p53 signaling pathway), and hsa04151 (PI3K-Akt signaling pathway), GO:0043124 (negative regulation of I-kappaB kinase/NF-kappaB signaling pathway), GO:0043409 (negative regulation of mitogen-activated protein kinase cascade), and GO:2001244 (positive regulation of intrinsic apoptotic signaling pathway) respectively.CONCLUSION EGCG inhibits the formation of DMH-induced CRC by regulating key pathways involved in tumorigenesis.

Direct inhibition of insulin-like growth factor-I receptor kinase activity by (-)-epigallocatechin-3-gallate regulates cell transformation.

Direct inhibition of insulin-like growth factor-1 receptor kinase activity by (-)-epgallocacatechin-3-gallate regulates cell transformation

Inhibitory Effects of (−)-Epigallocatechin-3-gallate on Esophageal Cancer

Effects of (−)-Epigallocatechin Gallate on Some Protein Factors Involved in the Epidermal Growth Factor Receptor Signaling Pathway

Green Tea Catechin, Epigallocatechin-3-Gallate, Inhibits Vascular Endothelial Growth Factor Angiogenic Signaling By Disrupting The Formation Of A Receptor Complex

Epigallocatechin Gallate Inhibits the Growth of Human Lung Cancer by Directly Targeting the EGFR Signaling Pathway.

Targeting receptor tyrosine kinases for chemoprevention by green tea catechin, EGCG

Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells

Epigallocatechin Gallate Inhibits Dimethylhydrazine-Induced Colorectal Cancer In Rats

(-)-Epigallocatechin-3-gallate Induces Non-Apoptotic Cell Death in Human Cancer Cells Via Ros-Mediated Lysosomal Membrane Permeabilization

Suppressing Glucose Metabolism with Epigallocatechin-3-gallate (EGCG) Reduces Breast Cancer Cell Growth in Preclinical Models

Epigallocatechin Gallate-Β-lactoglobulin Nanoparticles Improve the Antitumor Activity of EGCG for Inducing Cancer Cell Apoptosis

Epigallocatechin gallate (EGCG) suppresses growth and tumorigenicity in breast cancer cells by downregulation of miR-25

A New Epigallocatechin Gallate Derivative Isolated from Anhua Dark Tea Sensitizes the Chemosensitivity of Gefitinib Via the Suppression of PI3K/mTOR and Epithelial-Mesenchymal Transition

EGCG suppresses PD-1 expression of T cells via inhibiting NF-κB phosphorylation and nuclear translocation

The Epigenetic Modification of Epigallocatechin Gallate (EGCG) on Cancer

Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications

Preclinical Activities of Epigallocatechin Gallate in Signaling Pathways in Cancer

Cyclin D1 Degradation and P21 Induction Contribute to Growth Inhibition of Colorectal Cancer Cells Induced by Epigallocatechin-3-gallate

Epigallocatechin-3-Gallate Decreases Hypoxia-Inducible Factor-1 in Pancreatic Cancer Cells

Epigallocatechin Gallate Induces Chemopreventive Effects on Rats with Diethylnitrosamine‑induced Liver Cancer Via Inhibition of Cell Division Cycle 25A.